Highlightll：Submitted an IPO application to the Hong Kong Stock Exchange.
On June 8, the Hong Kong Stock Exchange (HKEX) website showed that the IPO application submitted by HighLight Pharmaceutical has been accepted. The joint sponsors for this IPO are CICC and CMB International.
Founded in 2017 and headquartered in Hangzhou, HighLight Pharmaceutical focuses on the discovery, development, and commercialization of therapies for autoimmune/inflammatory diseases. The company’s Chairman and CEO is Dr. Liang Congxin.
To date, HighLight Pharmaceutical has discovered seven small-molecule drug candidates, primarily for the treatment of autoimmune diseases and neurodegenerative diseases, including four candidates in clinical stages and three in preclinical stages.
In the autoimmune disease area, HighLight has two clinical-stage candidates:
TLL-018 (Jinuoxitinib) , the company’s core product, is a selective TYK2/JAK1 inhibitor currently undergoing two Phase III registrational trials in China for chronic spontaneous urticaria (CSU) and rheumatoid arthritis (RA).
HL-300, a potent, skin-restricted TYK2/JAK1/JAK2 inhibitor, is being developed as a topical treatment for mild-to-moderate atopic dermatitis (AD).
In the neurodegenerative disease pipeline, HighLight also has two clinical-stage candidates:
TLL-041, a brain-penetrant, selective TYK2/JAK1 inhibitor designed to treat neuroinflammatory diseases including Parkinson’s disease and Alzheimer’s disease. In March 2023, HighLight granted Biohaven exclusive rights to develop, manufacture, and commercialize TLL-041 outside Greater China.
HL-400, a brain-penetrant, selective NLRP3 inhibitor intended for the treatment of Parkinson’s disease.
Buy TLL-018/HL-300/TLL-041/HL-400 from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
